24.4 C
New York
Tuesday, August 16, 2022

Verastem Inc (VSTM) has experienced a tremendous increase in premarket – Here’s why?

2Verastem Inc (VSTM) has seen an increase of 25.72% in the premarket after the company announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766.

Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766

VSTM presented a brief oral presentation summarising new results from the current Phase 1/2 FRAME research on 19th September 2021. The FRAME trial is looking at VS-6766, a Verastem RAF/MEK inhibitor, in conjunction with defactinib. A Verastem FAK inhibitor is the one in which patients with low-grade serous ovarian cancer (LGSOC). The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2021.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


The overall response rate was 46 percent among the evaluable LGSOC patients. The ORR was 64 percent in individuals with KRAS mutant LGSOC. The ORR was 44% among patients with KRAS wild-type LGSOC. Ten (42%) of the evaluable patients had previously received MEK inhibitor treatment.

All patients had a median PFS of 23.0 months. Thirteen of the twenty-four patients (54%) were still on the trial as of the April 2021 data cutoff deadline.

For comparison, response rates for other treatments examined in recurrent LGSOC ranged from 6% to 26%, with mPFS ranging from 7.2 to 13.0 months.

VSTM reported Second Quarter 2021 Financial Results

VSTM reported second-quarter 2021 results on 3rd August 2021. Verastem Oncology had $114.1 million in cash, cash equivalents, and investments at the end of the second quarter of 2021.

Total revenue for the three months ending June 30, 2021, was $0.5 million, down from $4.3 million in the previous quarter.

In the 2021 Quarter, total operating expenditures were $16.4 million, compared to $25.6 million in the 2020 Quarter.

In the 2021 Quarter, selling, general, and administrative costs were $6.7 million, compared to $15.4 million in the 2020 Quarter. The drop of $8.7 million, or 56 percent, was largely due to the Company’s strategy change which resulted in decreased employee-related expenditures. In the 2021 Quarter, research and development costs were $9.7 million, compared to $9.3 million in the 2020 Quarter.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2887

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

DOWNLOAD FREE EBOOK

BEST INFLATION STOCKS 2022

We put together a list of the best stocks that

we think can explode over the next 12 months.

2888

SPECIAL GIFT

2889
2890
2891

  What you will Get ?

   Best Inflation

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

DOWNLOAD FREE EBOOK

BEST GROWTH STOCKS 2022

We put together a list of the best stocks that we

think can explode over the next 12 months.

2899

SPECIAL GIFT

2900
2901
2902

  What you will Get ?

   Best Growth

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

2903

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

2915

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

2839

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam